Immuron (IMRN) Other Non Operating Income (2018 - 2024)

Immuron (IMRN) posted Other Non Operating Income of -$183.93 for Q3 2024, up 98.99% on a QoQ basis from -$18191.1 in Q2 2024.

Analysis

Immuron (IMRN) Other Non Operating Income (2018 - 2024) Analysis & Trends

Immuron has reported Other Non Operating Income for 5 years, with the latest figure at -$183.93 in Q3 2024.

On a quarterly basis, Other Non Operating Income changed N/A year-over-year to -$183.93 in Q3 2024; TTM through Sep 2024 was -$815233.7, a N/A change from a year earlier, with the FY2025 full-year figure at $121.83, changed N/A from the prior year.
Other Non Operating Income was -$183.93 for Q3 2024 at Immuron, up from -$18191.1 in the prior quarter.
The five-year high for Other Non Operating Income was $236780.9 in Q4 2023, with the low at -$1.0 million in Q2 2021.
Average Other Non Operating Income over 3 years is -$203808.4, with a median of -$9187.5 recorded in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn
10	Immuron	7.14 Mn	-1.88 Mn	-

Historic Data

Download Data